Strategic and Business Planning

The Board has developed a Strategic Plan for 2010-2012. This can be found at http://www. anzup.org.au/content.aspx?page=strategicplan. Part of the plan involves identification and appointment of Directors with expertise in legal, corporate, accounting and fundraising issues. Other key objective are to continue to build research capacity, extend collaborations and to mentor young investigators.

Changes in state of affairs:

The Executive Director (John Ramsay) resigned from the Board on 13 April 2010.

A new Executive Officer (Margaret McJannett) was employed as of January 2011.

The Board recommended changes to its composition which came into effect on the passing of the special resolution to amend ANZUP’s constitution at the extraordinary general meeting (EGM) held on Friday 25 June 2010 at 12:30pm to 1:15pm.

The first Annual General Meeting was held on Friday 25 June 2010 at 1:15pm to 3:00pm (AEST). The Board was not able to hold the first ANZUP Annual General Meeting in accordance with the usual requirements of the Corporations Act 2001 (Cth) because the company audit was not able to be completed by that deadline. An application was made to ASIC to extend the time by which ANZUP may hold its first AGM to 30 June 2010 pursuant to s.250P of the Corporations Act 2001. This application was granted.

In accordance with section 8.13(a) of the ANZUP Constitution, Ian Davis must resign as an elected Director but is eligible to be re-elected and has been nominated for re-election.

Matters affecting ANZUP operations and state of affairs in future financial years:

At the time of preparation of this report, approval of recurrent funding from Cancer Australia under its Support for Clinical Trials scheme had not yet been confirmed after 31 December 2011. This funding will be critical for the future operations of ANZUP. The Board anticipates that Cancer Australia is very likely to approve ongoing funding, at least for a further 18 months.

Additional funding sources will need to be identified in order to support the proposed expansion of activities of ANZUP.

Likely developments in operations and expected results:

ANZUP plans to continue its employment of an Executive Officer and to employ a Project Officer. Further expansion in staff may be necessary depending on the scope of activities. This will only be possible with additional funding. ANZUP plans to continue to develop clinical trials and aims to activate 1-2 new protocols per year.